Eli Lilly and Co
NYSE:LLY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Eli Lilly and Co
NYSE:LLY
|
US |
|
L
|
Louisiana-Pacific Corp
F:LP3
|
US |
Intrinsic Value
The intrinsic value of Eli Lilly and Co (LLY) under the Base Case is 1 139.65 USD per share.
Compared with the current market price of 1 269.68 USD, the stock appears
Overvalued by 10% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Eli Lilly and Does
Eli Lilly is a pharmaceutical company that discovers, develops, makes, and sells prescription medicines. Its products treat major disease areas such as diabetes, obesity, cancer, immune disorders, and neurological conditions. The company does not sell consumer goods; it sells regulated drugs that patients get through doctors, pharmacies, hospitals, and health plans.
- Headquarters
- United States of America US
- Employees
- 50 000
- IPO date
- Jul 9, 1970
Eli Lilly and has a wide economic moat
Patents and legal protection for its clinical trial data keep competitors from freely copying Lilly’s key medicines, allowing it to earn more than sellers of generic drugs. These protections cover treatments across diabetes, obesity, cancer and immune diseases, spreading its protection across several medicines rather than a single product.
Read the full moat analysis
Revenue & Expenses Breakdown
Eli Lilly and Co
Earnings Waterfall
Eli Lilly and Co
The intrinsic value for Eli Lilly and Co (LLY) under the Base Case is 1 139.65 USD.
Compared with the current market price of 1 269.68 USD, the stock appears Overvalued by 10% .